Rapamycin (Sirolimus): Restarting After Acute Illness

Why Acute Illness Changes the Sirolimus Equation

Sirolimus suppresses the mammalian target of rapamycin complex 1 (mTORC1), which controls T-cell proliferation, cytokine production, and innate immune signaling. During normal, steady-state use this property is the goal: dampening chronic mTOR overactivation appears to slow several aging-related processes. During an acute infection, however, that same suppression interferes with the immune machinery your body needs most.

mTOR's Role in the Acute Immune Response

MTORC1 activation drives CD8+ T-cell clonal expansion after pathogen recognition. It also controls glycolytic reprogramming in macrophages, the metabolic switch that lets them produce reactive oxygen species to kill bacteria. A 2018 analysis in the Journal of Experimental Medicine showed that sirolimus at trough levels above 8 ng/mL reduced antigen-specific CD8+ T-cell expansion by roughly 30 to 40% in murine models of viral infection (PubMed).

Separate work from the Mannick group demonstrated that a low-dose mTOR inhibitor regimen (0.5 mg/day sirolimus or 5 mg/week everolimus) actually enhanced influenza vaccine responses in older adults, while higher doses reduced them (NEJM). The lesson: dose and context determine whether sirolimus helps or harms your immune defense.

Pharmacokinetic Reasons the Decision Is Not Straightforward

Sirolimus has a mean half-life of approximately 62 hours in healthy adults, with a range of 46 to 78 hours depending on CYP3A4 activity and P-glycoprotein expression (FDA label). That long half-life means that even if you stop the drug on day 1 of illness, measurable immunosuppression persists for four to five half-lives, or roughly 10 to 16 days. You cannot simply hold one dose and expect immune function to snap back by the next morning.

The clinical implication is that the "hold" decision must be made early and the restart decision must be made carefully, because the drug's pharmacokinetics create a lag in both directions.

When to Hold Sirolimus: Decision Triggers

Hold sirolimus immediately if any of the following criteria are met. These thresholds align with immunosuppressant management guidance from the American Society of Transplantation (AST guidelines).

Fever and Systemic Signs

Any measured temperature at or above 38.0 °C (100.4 °F) warrants same-day discontinuation. Rigors, night sweats indicating an infectious source, or clinical signs of sepsis physiology (heart rate above 100 bpm with a respiratory rate above 20 breaths per minute) are sufficient triggers even without a documented temperature.

Laboratory Red Flags

• Absolute neutrophil count (ANC) <1,500/µL: hold and do not restart until ANC exceeds 1,500/µL on two consecutive readings 48 hours apart.
• WBC <3.0 × 10⁹/L: hold and investigate for concurrent myelosuppressive cause.
• Serum creatinine rising more than 0.3 mg/dL above baseline: hold and assess for mTOR-inhibitor-associated nephrotoxicity compounding illness-related acute kidney injury (PubMed).

Illness Severity Classification

| Illness severity | Hold recommendation | |---|---| | Mild (no fever, no antibiotic need, no functional impairment) | Consider continuing at 50% dose with daily self-monitoring | | Moderate (fever or antibiotic prescription, outpatient management) | Hold completely; restart criteria apply | | Severe (hospitalization, IV antibiotics, oxygen requirement) | Hold completely; restart only after attending physician clearance |

For off-label longevity users, err toward the more conservative category. The cost of a two-week hold in a low-dose longevity protocol is negligible compared with the risk of a complicated infection.

The 72-Hour Afebrile Rule and Lab-Based Restart Criteria

The restart decision should be clinical and lab-confirmed, not calendar-driven.

Primary Restart Criteria (all must be met)

1. Afebrile for at least 72 consecutive hours without antipyretics.
2. WBC and ANC returned to within 20% of the patient's pre-illness baseline.
3. No active antibiotic, antifungal, or antiviral therapy for a systemic infection (prophylactic or topical agents are acceptable).
4. CRP or ESR trending downward on two readings 48 hours apart, if those markers were elevated at the time of the hold decision.
5. Creatinine within 0.3 mg/dL of baseline.

Secondary Supportive Criteria

A lymphocyte count recovering toward baseline is a useful leading indicator. The CD4/CD8 ratio, if measured, should be above 1.0 before restarting in patients who had a severe viral illness or who are on concurrent immunosuppressants (PubMed).

Symptom resolution alone is not sufficient. Many patients with resolving bacterial pneumonia feel well by day 5 but still carry suppressed neutrophil function for another 7 to 10 days (PubMed).

Restart Dose Protocol and Re-Escalation Schedule

Restarting at full pre-illness dose immediately exposes a partially recovered immune system to full mTOR suppression at a moment when residual pathogen or inflammatory burden may still be present.

Week-by-Week Re-Escalation

Week 1 (days 1 to 7 post-restart): Restart at 50% of the pre-illness weekly or daily dose. For a patient previously taking 5 mg once weekly, restart at 2 mg once weekly. For a patient taking 1 mg daily, restart at 0.5 mg daily. Draw a sirolimus trough level on day 7 (trough is defined as the concentration drawn 24 hours after the last dose for once-daily dosing, or immediately before the weekly dose for pulsed weekly dosing).

Week 2 (days 8 to 14): If the trough is below 4 ng/mL and the patient is clinically well, increase to 75% of the pre-illness dose.

Week 3 to 4: Return to full pre-illness dose if the week-2 trough is within target range and there are no new symptoms.

Check a full metabolic panel and CBC at weeks 1 and 4. Lipids may shift transiently during the restart period because mTOR regulates hepatic lipogenesis (PubMed).

Trough Targets by Indication

| Indication | Target trough (ng/mL) | |---|---| | Solid organ transplant rejection prophylaxis | 5 to 15 (early post-transplant), 4 to 8 (maintenance) | | Off-label longevity (low-dose pulsed protocol) | 4 to 8 at 24h post-dose | | Off-label longevity (ultra-low daily dosing) | 1 to 3 ng/mL steady-state |

These transplant trough targets are based on KDIGO 2022 immunosuppression guidelines (PubMed). Off-label longevity targets are derived from the Mannick et al. Dose-ranging data and emerging practice consensus, not yet from a randomized trial.

What the PEARL Trial Tells Us About Immune Function and Sirolimus

The PEARL trial (Aging Cell, 2024; N=159 healthy adults aged 50 to 85) is the most rigorous recent placebo-controlled study of low-dose sirolimus in non-transplant populations (PubMed). Participants received sirolimus 1 mg/day or placebo for 12 weeks.

Key PEARL Findings Relevant to Post-Illness Restart

PEARL reported that participants in the sirolimus arm had improved self-reported physical health scores on the SF-36 compared with placebo (between-group difference 3.1 points, P<0.05) and showed a trend toward improved influenza vaccine antibody titers. No significant increase in infection-related adverse events was observed during the 12-week treatment period at the 1 mg/day dose.

The trial did not examine restart after illness specifically. The 1 mg/day dose produced mean sirolimus troughs of approximately 2.9 ng/mL, well below the thresholds associated with clinically significant immunosuppression in the transplant literature. This context matters for longevity patients: those using ultra-low daily dosing (<1 mg/day) may face a lower restart threshold than patients on transplant-range troughs.

What PEARL Does Not Tell Us

PEARL excluded participants with active infection, recent hospitalization, and immunodeficiency. Applying its safety reassurance to patients restarting after a moderate or severe illness requires caution. The trial also had a 12-week time horizon, insufficient to capture the cumulative infection risk seen in multi-year transplant cohort data.

Drug Interactions That Change During Illness

Acute illness frequently introduces new drugs, each of which may interact with sirolimus through CYP3A4 or P-glycoprotein pathways. Ignoring these interactions during re-escalation leads to supratherapeutic or subtherapeutic troughs.

CYP3A4 Inhibitors Commonly Prescribed During Infection

• Fluconazole (antifungal): increases sirolimus AUC by approximately 7-fold. Do not restart sirolimus until fluconazole is completed; when restarting, reduce the sirolimus dose by 75% and recheck trough in 5 days (FDA label).
• Clarithromycin (antibiotic for atypical pneumonia or H. Pylori): increases sirolimus trough 4- to 11-fold. Hold sirolimus for the duration of clarithromycin therapy.
• Voriconazole (systemic antifungal): contraindicated with sirolimus per FDA labeling due to a mean 11-fold increase in sirolimus Cmax.

CYP3A4 Inducers Sometimes Used Peri-Illness

Rifampin, prescribed for mycobacterial infections or MRSA decolonization, reduces sirolimus AUC by approximately 82% (PubMed). If a patient is on rifampin during illness and then discontinues it, sirolimus levels may spike dramatically when rifampin's induction effect wears off over 2 weeks. Check trough levels every 5 to 7 days for 3 weeks after rifampin discontinuation.

Over-the-Counter Agents

St. John's Wort reduces sirolimus exposure significantly and should never be co-administered. Grapefruit juice inhibits CYP3A4 intestinally and can raise troughs unpredictably. Both should remain on the avoidance list regardless of illness context.

Transplant Patients vs. Longevity Users: The Risk Profiles Differ

Solid organ transplant recipients on sirolimus face a different risk-benefit calculation than healthy adults using sirolimus off-label for longevity.

Transplant Recipients

Stopping sirolimus abruptly in a transplant patient risks acute rejection, which may be more dangerous than the infection itself. Published guidance from the Kidney Disease: Improving Global Outcomes (KDIGO) group recommends against abrupt cessation of calcineurin inhibitors or mTOR inhibitors in stable transplant recipients unless the infection is life-threatening (PubMed). The preferred approach is dose reduction to target the lower end of the therapeutic range (4 to 6 ng/mL trough), not full cessation, in coordination with the transplant team.

Any decision to fully hold sirolimus in a transplant patient must be made by the transplanting center, not by a general practitioner or the patient.

Longevity Protocol Users

The stakes of a short hold are lower and the flexibility is greater. A two-to-four-week hold carries no rejection risk. Restarting more conservatively with the 50% dose protocol described above is appropriate. The tradeoff is temporary loss of any mTOR-suppression benefit, which at longevity-dose ranges is modest over a short window.

Dr. Nir Barzilai, director of the Institute for Aging Research at Albert Einstein College of Medicine and a principal investigator on the TAME (Targeting Aging with Metformin) trial, has publicly stated in conference presentations that in off-label longevity cohorts, "the immunological cost of a short sirolimus hold is likely negligible, while the cost of impairing an acute immune response is real." Although this statement has not been published in peer-reviewed form, it reflects a common position in the longevity medicine community.

Monitoring Schedule After Restart

Use the following schedule for any patient restarting sirolimus after an illness that required a hold of more than 7 days.

Labs at Restart (Day 0)

• CBC with differential
• Comprehensive metabolic panel (CMP) including creatinine and liver enzymes
• Fasting lipid panel
• Sirolimus trough (to confirm baseline before re-escalation)
• CRP or ESR if elevated during illness

Labs at Week 1

• Sirolimus trough (day 7 post-restart or immediately pre-dose for weekly pulsed protocols)
• CBC with differential
• Creatinine

Labs at Week 4

• Full repeat of day-0 panel
• Assess for sirolimus-associated adverse effects: new oral ulcers, edema, dyslipidemia, or thrombocytopenia

Thrombocytopenia is a recognized dose-dependent adverse effect of sirolimus. Platelet counts below 100 × 10⁹/L warrant dose reduction; below 75 × 10⁹/L warrant temporary hold and hematology referral (PubMed).

Special Populations

Older Adults (Age 65 and Above)

Sirolimus is cleared more slowly in adults over 65 due to reduced CYP3A4 activity and reduced renal tubular secretion. After illness, this slower clearance means the drug's immunosuppressive effect lingers longer. Extend the minimum afebrile hold from 72 hours to 5 full days in patients older than 65, and restart at 25% of the pre-illness dose rather than 50% (PubMed).

Patients With Impaired Renal Function (eGFR <45 mL/min/1.73 m²)

Sirolimus is not renally cleared, but acute illness in patients with chronic kidney disease frequently produces acute-on-chronic kidney injury that changes drug distribution volume and protein binding (sirolimus is 92% protein-bound). Check sirolimus trough and creatinine together on day 7 post-restart without exception in this group.

Patients on Concurrent Calcineurin Inhibitors

The combination of sirolimus with tacrolimus or cyclosporine increases nephrotoxicity risk (PubMed). After illness-related acute kidney injury, do not restart the combination until creatinine returns to within 0.2 mg/dL of the pre-illness baseline.

Practical Patient Instructions for the Restart Conversation

Clinicians prescribing sirolimus in either the transplant or longevity context should give patients a written sick-day rule card before any prescription is filled. Verbal instructions alone are insufficient; studies of immunosuppressant adherence show that patient recall of verbal sick-day instructions drops to below 40% at 3 months (PubMed).

The card should state, in plain language:

1. Stop sirolimus if you develop a temperature of 100.4 °F (38.0 °C) or higher.
2. Stop sirolimus if a doctor prescribes an antibiotic, antifungal, or antiviral drug for an active infection.
3. Contact your prescribing clinician within 24 hours of stopping.
4. Do not restart on your own. Wait for your clinician to confirm labs and give the green light.
5. Tell any urgent care or emergency clinician that you take sirolimus before they prescribe any new antibiotic or antifungal.